ClinicalTrials.gg
RecruitingNCT07141017REVINSPAUpdated Aug 26, 2025

Initial Standardized Global Review in Axial Spondyloarthritis

An interventional study of Initial standardized global review in Axial Spondylarthritis (axSpA), sponsored by Association de Recherche Clinique en Rhumatologie. Recruiting at 21 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Association de Recherche Clinique en Rhumatologie · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Planned enrollment
17th of 30
154 · median 188
Started
2025
with 2 others
No phase
13 of 40
6 open now
Primary completion
2027-05
later than 5 of 10 live
Registered
39th of 40
by date
Lead sponsor
2 of 40
Association de Recherche Clinique en Rhumatologie

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 39th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

This study will be a pragmatic, cluster-randomized, controlled study with two parallel arms ( 'intervention' and 'usual care' (UC) arms) of one year duration.

The study will be open-label, but centers randomized in the UC arm will not be aware of the intervention performed in the 'intervention' centers.

The primary objective of this study will be to determine whether participation in a standardized global review (that includes assessment of disease domains and education ) as soon as possible after diagnosis of axial spondyloarthritis has a beneficial impact on patient knowledge of the disease at 12 months. The primary endpoint will be the change in the SPAKE (SPondyloArthritis Knowledge Questionnaire) questionnaire between M0 and M12.

03

Conditions studied

  • Axial Spondylarthritis (axSpA)

Keywords

  • Rheumatology
  • Initial standardized global review
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (but age \<80years) with a diagnosis of axial spondyloarthritis determined by the treating rheumatologist within the 12 months preceding the baseline visit, who have completed the and have the ability to complete all study activities.

Exclusion criteria

Exclusion Criteria:

  • Patients who have already received a specific (or plan to receive in the coming 12 months) and dedicated program/global evaluation including education on the disease or treatments.
  • Patients with any physical or mental condition that may affect understanding of the intervention or adherence to treatment (e.g. major depression or substance/alcohol use - might have impact on the outcomes of interest in the study).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Other: Initial standardized global review

  • No intervention
    Usual care arm

Interventions

  • OtherInitial standardized global review

    The intervention under study will be the initial standardized global review, which will be performed as soon as axial spondyloarthritis is diagnosed (less than 12 months from diagnosis is mandatory) and only at the baseline visit. This review includes both the assessment of different domains of the disease, but also the education and information on such different domains of the disease and its management The domains assessed during the intervention will be: diagnosis of spondyloarthritis, spondyloarthritis phenotype, disease activity, disease severity and function, treatment adherence and comorbidities. At the end of the intervention, a detailed medical report on this initial standardized global review will be produced and sent to the patient, their rheumatologist, their general practitioner, and their dispensing pharmacist.

06

What researchers measure

Primary outcomes

  1. The change in patient knowledge of the disease.

    The primary endpoint will be the change in the SPAKE questionnaire

    Time frame: Visits Day 0 and Month 12

Secondary outcomes

  1. Treatment

    Treatment in both groups will be evaluated NSAID intake and % of patients receiving csDMARD/bDMARD/tsDMARD

    Time frame: Visits Day 0 and Month 12

  2. The ability to cope with the disease

    The ability to cope with the disease will be evaluated by disease coping change between Day 0 and Month 12 in both groups using the Coping Scale from the RAID questionnaire

    Time frame: Visits Day 0 and Month 12

  3. Knowledge on b/tsDMARDs

    Knowledge on b/tsDMARDs, only in patients with b/tsDMARD, will be evaluated by the BioSECURE'21 questionnaire

    Time frame: Visits Day 0 and Month 12

  4. Adherence to axSpA treatments

    Adherence to axSpA treatments in both groups will be evaluated by the CQR5 questionnaire

    Time frame: Visits Day 0 and Month 12

  5. Disease activity

    Disease activity will be evaluated by the disease activity score (ASDAS) change in both groups

    Time frame: Visits Day 0 and Month 12

  6. Number of comorbidities

    Number of comorbidities managed according to recommendations in both groups

    Time frame: Visit Month 12

  7. Function change

    Function change in both groups between will be evaluated by the BASFI questionnaire

    Time frame: Visits Day 0 and Month 12

  8. Quality of life change

    Quality of life change in both groups will be evaluated by the ASAS-HI questionnaire

    Time frame: Visits Day 0 and Month 12

  9. Work impairment

    Work impairment will be evaluated by the WPAI questionnaire

    Time frame: Visit Month 12

  10. Assessment of health services resources use

    Assessment of health services resources use will be evaluated by self-questionnaire

    Time frame: Visit Month 12

  11. The patient's perception of the benefits of this type of initial global standardized review on patient's follow-up and the treating rheumatologist's perception of the benefits of this type of initial global standardized review on patient follow-up

    The patient's perception of the benefits of this type of initial global standardized review on patient's follow-up and the treating rheumatologist's perception of the benefits of this type of initial global standardized review on patient follow-up will be evaluated by the Likert scale

    Time frame: Visit Month 12

  12. The sources of information accessed by patients

    The sources of information accessed by patients in both groups be evaluated with the percentage of patients who participated in a therapeutic education programme

    Time frame: Visits Day 0 and Month 12

07

Study locations

11 of 21 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 24 months is below that.

Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 26, 2025
StartActual
May 12, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07141017
Lead sponsor
Association de Recherche Clinique en Rhumatologie
Collaborators
RCTs
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
May 12, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 26, 2025

Study contacts

Anna Molto
Contact
anna.molto@aphp.fr
+33158412576

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion